Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for Graves' Orbitopathy
NCT04598815Phase 2Unknown
- Sponsor
- University of Pisa
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nab-sirolimus in Graves Orbitopathy (GO) (2 arms), sponsored by University of Pisa. Primary endpoint: Graves' Orbitopathy Overall Response at 24 weeks. Status: unknown.
02
Drugs
nab-sirolimus
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on NCT04598815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04598815.